1254802-65-7

Upstream product

• 1187323-16-5 cis-(2R,4R)-4-phenyltetral-2-yl tosylate 
• 38661-84-6 (E)-1,4-diphenylbut-1-en-3-one 
• 103-79-7 1-phenyl-acetone 
• 100-52-7 benzaldehyde 
• 150402-73-6 4-phenyl-2-tetralone 
• 1353637-93-0 (+)-(R)-4-phenyl-3,4-dihydronaphthalen-2(1H)-one 
• 1353637-95-2 2-methyl-N-(4-phenyl-3,4-dihydronaphthalen-2-yl)propane-2-sulfinamide 
• 1187323-15-4 (+)-(2R,4R)-4-phenyl-1,2,3,4-tetrahydronaphthalene-2-ol 

Downstream Products

• 1350817-05-8 (-)-N-(2S,4R)-trans-(4-phenyl-1,2,3,4-tetrahydronaphthalen-2-yl)propionamide 
• 150576-70-8 (-)-trans-1-phenyl-3-amino-1,2,3,4-tetrahydronaphthalene 

Relevant academic research and scientific papers

Synthesis and configuration determination of all enantiopure stereoisomers of the melatonin receptor ligand 4-phenyl-2-propionamidotetralin using an expedient optical resolution of 4-phenyl-2-tetralone

An efficient and practical approach for the synthesis of all four stereoisomers of the MT2 melatonin receptor ligand 4-phenyl-2-propionamidotetralin (4-P-PDOT), each in enantiomerically pure form (ee > 99.9%), was developed. The strategy involved an optical resolution procedure of the key precursor (±)-4-phenyl-2-tetralone with the unusual resolving agent (S)-mandelamide, through the formation of four dihydronaphtalene-spiro-oxazolidin-4-one diastereomers. Interestingly, NMR experimental observations in combination with geometric calculations, provided unambiguous configuration assignments of all stereocenters of the key spiro stereoisomers. Cleavage of each single spiro diastereomer under acidic conditions gave enantiopure (R)- or (S)-4-phenyl-2-tetralone, which were then converted to each 4-P-PDOT single enantiomer by using stereoselective reactions.

THERAPEUTIC COMPOUNDS

The invention relates to protein binding interacting/binding compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating 5-HT2C disorders, including diseases and disorders medi